Phospholamban antibody (pSer16, pThr17)

Catalog No. ABIN7269330

Product Details anti-Phospholamban Antibody

Target: Phospholamban (PLN)

Binding Specificity: pSer16, pThr17

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Phospholamban antibody is un-conjugated

Application: Western Blotting (WB)

Purpose: Phospho-PLN-S16/T17 Rabbit pAb

Cross-Reactivity: Human, Mouse, Rat

Characteristics: Phosphorylated Antibodies

Purification: Affinity purification

Immunogen: A synthetic phosphorylated peptide around of human Phospho-PLN-S16/T17.

Isotype: IgG

Application Details

Application Notes: WB,1:500 - 1:2000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Avoid freeze / thaw cycles.

Target Details for Phospholamban

Target: Phospholamban (PLN)

Alternative Name: PLN (PLN Products)

Background: The protein encoded by this gene is found as a pentamer and is a major substrate for the cAMP-dependent protein kinase in cardiac muscle. The encoded protein is an inhibitor of cardiac muscle sarcoplasmic reticulum Ca(2+)-ATPase in the unphosphorylated state, but inhibition is relieved upon phosphorylation of the protein. The subsequent activation of the Ca(2+) pump leads to enhanced muscle relaxation rates, thereby contributing to the inotropic response elicited in heart by beta-agonists. The encoded protein is a key regulator of cardiac diastolic function. Mutations in this gene are a cause of inherited human dilated cardiomyopathy with refractory congestive heart failure, and also familial hypertrophic cardiomyopathy.,CMD1P,CMH18,PLB,PLN,Cancer,Signal Transduction,Endocrine & Metabolism,Neuroscience,Calcium Signaling,Cardiovascular,Heart,Contractility,PLN

Molecular Weight: 6kDa

Gene ID: 5350

UniProt: P26678

Pathways: Negative Regulation of Transporter Activity